Cite
CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course.
MLA
Pius-Sadowska, Ewa, et al. “CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course.” International Journal of Molecular Sciences, vol. 23, no. 19, Oct. 2022, p. 11338. EBSCOhost, https://doi.org/10.3390/ijms231911338.
APA
Pius-Sadowska, E., Niedźwiedź, A., Kulig, P., Baumert, B., Sobuś, A., Rogińska, D., Łuczkowska, K., Ulańczyk, Z., Wnęk, S., Karolak, I., Paczkowska, E., Kotfis, K., Kawa, M., Stecewicz, I., Zawodny, P., & Machaliński, B. (2022). CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course. International Journal of Molecular Sciences, 23(19), 11338. https://doi.org/10.3390/ijms231911338
Chicago
Pius-Sadowska, Ewa, Anna Niedźwiedź, Piotr Kulig, Bartłomiej Baumert, Anna Sobuś, Dorota Rogińska, Karolina Łuczkowska, et al. 2022. “CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course.” International Journal of Molecular Sciences 23 (19): 11338. doi:10.3390/ijms231911338.